U.S. Markets open in 3 hrs 36 mins

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MO, CVET, SDC and PLT

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.      

Altria Group, Inc. (MO)
Class Period: December 20, 2018 to September 24, 2019
Lead Plaintiff Deadline: December 2, 2019

The complaint alleges that during the class period Altria Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Altria had conducted insufficient due diligence into JUUL prior to the Company’s $12.8 billion investment, or 35% stake, in JUUL; (ii) Altria consequently failed to inform investors, or account for, material risks associated with JUUL’s products and marketing practices, and the true value of JUUL and its products; (iii) all of the foregoing, as well as mounting public scrutiny, negative publicity, and governmental pressure on e-vapor products and JUUL made it reasonably likely that Altria’s investment in JUUL would have a material negative impact on the Company’s reputation and operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Get additional information about the MO lawsuit: http://www.kleinstocklaw.com/pslra-1/altria-group-inc-loss-submission-form?from=3&id=4611 

Covetrus, Inc. (CVET)
Class Period: February 8, 2019 to August 12, 2019
Lead Plaintiff Deadline: November 29, 2019

The CVET lawsuit alleges that throughout the class period, Covetrus, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company’s separation from Henry Schein.

Get additional information about the CVET lawsuit: http://www.kleinstocklaw.com/pslra-1/covetrus-inc-loss-submission-form?from=3&id=4611 

SmiledirectClub, Inc. (NASDAQ:SDC)
Class Period:  investors who purchased SmileDirectClub Class A common stock (a) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s September 12, 2019 initial public offering, or (b) during the period from September 8, 2019 through October 2, 2019.
Lead Plaintiff Deadline: December 2, 2019

The complaint alleges SmiledirectClub, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) administrative personnel, rather than licensed doctors, provided treatment to the Company’s customers and monitored their progress; (2) as a result, the Company’s practices did not qualify as teledentistry under applicable standards; (3) as a result, the Company was subject to regulatory scrutiny for the unlicensed practice of dentistry; (4) the efficacy of the Company’s treatment was overstated; (5) the Company had concealed these deceptive marketing practices prior to the IPO; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Get additional information about the SDC lawsuit: http://www.kleinstocklaw.com/pslra-1/smiledirectclub-inc-loss-submission-form?from=3&id=4611 

Plantronics, Inc. (PLT)
Class Period: July 2, 2018 to November 5, 2019
Lead Plaintiff Deadline: January 13, 2020

The PLT lawsuit alleges that throughout the class period, Plantronics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had engaged in channel stuffing to artificially boost sales; (2) the Company’s internal control over inventory levels was not effective; (3) the Company had not adequately monitored inventory levels ahead of multiple product launches, where the new models would displace demand for aging products; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Get additional information about the PLT lawsuit: http://www.kleinstocklaw.com/pslra-1/plantronics-inc-loss-submission-form?from=3&id=4611 

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

  • Tesla will mark the beginning of the end for this bull market, warns Ralph Nader
    Business
    MarketWatch

    Tesla will mark the beginning of the end for this bull market, warns Ralph Nader

    Apparently so, according to consumer advocate and former presidential candidate Ralph Nader, who issued a stark warning this week, not only on the electric-car maker's pricey stock, but on the stock market as a whole. “Deep in debt, selling less than 400,000 vehicles last year and challenged by several competing electric car models in 2020, Tesla's stock valuation stunningly exceeds VW which sold over 10 million vehicles last year,” Nader added in a follow-up tweet. Of course, his stance didn't sit well with Tesla fans.

  • Retirement: What Happens If a Spouse Dies?
    Business
    Investopedia

    Retirement: What Happens If a Spouse Dies?

    This form names the person or people who will receive your IRA and in what proportions. You can amend the form at any time, but whoever is on the form upon your death will receive the funds—even if they are an ex-spouse or a disinherited child. "If you name multiple people as beneficiaries of one retirement plan, they all take required minimum distributions (RMDs) based on the life expectancy of the eldest beneficiary (i.e., the person who has to take out the largest distributions).

  • Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 15%
    Business
    TipRanks

    Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 15%

    The stock analysts at Goldman Sachs have been busy. All of this is bread and butter for TipRanks, a platform that makes financial recommendations accountable, and expensive institutional datasets available, to all investors. Three tech stocks that usually fly under the radar – but Goldman sees them all with more than 15% upside potential in the coming year.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of FCEL earnings conference call or presentation 22-Jan-20 3:00pm GMT

    Q4 2019 FuelCell Energy Inc Earnings Call

  • When Should You Buy The Walt Disney Company (NYSE:DIS)?
    Business
    Simply Wall St.

    When Should You Buy The Walt Disney Company (NYSE:DIS)?

    The Walt Disney Company (NYSE:DIS) saw significant share price movement during recent months on the NYSE, rising to highs of US$152 and falling to the lows of US$129. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Walt Disney's current trading price of US$142 reflective of the actual value of the large-cap?

  • FICO scores, the 'most important numbers in your financial life,' are about to change
    Business
    USA TODAY

    FICO scores, the 'most important numbers in your financial life,' are about to change

    Americans who fall behind on loan payments, rack up rising debt or take out personal loans to consolidate debt will likely see their credit scores fall under updates planned for the popular FICO scores, according to Fair Isaac Corp., the creator FICO scores. “Most consumers will see less than a 20-point swing in either direction,” David Shellenberger, FICO's vice president, product management, scores, said in a statement on Thursday. About 40 million, he said, will see a sharper shift upward in scores, and 40 million will be hit with a similar-sized drop, Shellenberger said.

  • Ericsson shares slump as earnings weighed by higher costs
    Business
    MarketWatch

    Ericsson shares slump as earnings weighed by higher costs

    Shares in Ericsson AB (ERIC) slumped as much as 8.2% in early trade Friday after seeing fourth-quarter earnings weighed by higher costs. The telecommunications equipment company (ERIC)(SE:ERIC)(SE:ERIC) saw costs rise in the quarter as it invested in acquisitions, digitization, security and ethics and compliance. Citi analyst Amit Harchandani said he expects consensus 2020 earnings before interest and tax expectations at Ericsson to move lower by 5%-10% on the higher operating expenditure.

  • Britain's Prince Charles appears to snub Pence
    World
    Associated Press Videos

    Britain's Prince Charles appears to snub Pence

    Britain's Prince Charles appeared to snub U.S. Vice President Mike Pence on Thursday during his arrival to the World Holocaust Forum event. Jan.

  • Business
    TheStreet.com

    7 Low-Risk Investments With High Returns in 2020

    The classic risk-free investment is Treasury securities, but even they carry some degree of price risk from changes in interest rates, though the risk of default is slim to none. To be clear, dividend-paying stocks do carry risk as they are still subject to the same factors that impact the stock market. Investing for dividend yield is about finding those companies that pay higher dividends as a source of yield.

  • Business
    TheStreet.com

    Intel Shares Reach Two-Decade High After Blasting Q4 Earnings Forecasts

    Intel Corp. shares are set to open at the highest levels in nearly two decades Friday after the semiconductor maker topped Wall Street's fourth quarter earnings forecast and predicted robust 2020 sales amid an emerging rebound in global chip markets. Intel said non-GAAP earnings for the three months ending in December rose 18.8% to $1.52 per share, smashing the Street consensus forecast of $1.25 as overall revenues rose 8% to $20.2 billion, topping analysts' estimates of a $19.2 billion tally. Intel also forecast 2020 sales of around $73.5 billion, citing a increases in chip purchases from 'hyperscale' cloud providers adding chips to the growing data centers.

  • Dow Jones Futures: Intel, Atlassian Soar On Earnings, Boost 3 Leaderboard Stocks; Broadcom Rises On Apple Deal
    Business
    Investor's Business Daily

    Dow Jones Futures: Intel, Atlassian Soar On Earnings, Boost 3 Leaderboard Stocks; Broadcom Rises On Apple Deal

    Dow Jones futures and S&P 500 futures edged higher Thursday, while Nasdaq futures rose modestly, after the stock market rally showed continued resilience amid an expanding China coronavirus crisis. Chip giant Intel and software maker Atlassian crushed earnings views. Intel stock jumped in extended trade, with AMD stock and Nvidia stock also getting a lift.

  • Mark Cuban: Where the ‘frothy’ market goes from here depends on one thing
    Business
    MarketWatch

    Mark Cuban: Where the ‘frothy’ market goes from here depends on one thing

    “Interest rates were a lot different back then,” he continued. A day earlier, fellow billionaire Paul Tudor Jones, from the sidelines of the World Economic Forum in Davos, said we are currently in the “craziest monetary and fiscal mix in history,” and, at least to him, it's reminiscent of 1999. What happens next in the stock market, he said, depends where interest rates go from here.

  • Wells Fargo former CEO John Stumpf fined $17.5 million, banned for life from banking
    Business
    American City Business Journals

    Wells Fargo former CEO John Stumpf fined $17.5 million, banned for life from banking

    Wells Fargo former Chairman and CEO John Stumpf has agreed to pay a fine of $17.5 million and accept a lifetime ban from the banking industry in a settlement the Office of the Comptroller of the Currency announced Thursday. Hope Hardison, Wells Fargo's (NYSE: WFC) former chief administrative officer and director of corporate human resources, agreed to pay a fine of $2.25 million and a personal cease and desist order that requires her to refrain from certain conduct in the future. The bank's former Chief Risk Officer Michael Loughlin will pay a fine of $1.25 million and a personal cease and desist order.

  • What to watch in the markets: Friday, Jan 24
    Business
    Yahoo Finance Video

    What to watch in the markets: Friday, Jan 24

    Yahoo Finance's Myles Udland highlights the day's market action and upcoming earnings to drive headlines.

  • These 10 Rules Made Warren Buffett a Billionaire
    Business
    MoneyWise

    These 10 Rules Made Warren Buffett a Billionaire

    Warren Buffett may be worth tens of billions, but he still lives simply, and his strategies for smart investing and amassing wealth aren't too complicated either. Buffett's first key to prosperity has little to do with picking stocks. "Without good communication skills, you won't be able to convince people to follow you even though you see over the mountain and they don't," Buffett once told a Stanford MBA student.

  • Surgical Robotics Leader Dives As Sales, Earnings Growth Decelerate
    Business
    Investor's Business Daily

    Surgical Robotics Leader Dives As Sales, Earnings Growth Decelerate

    Surgical robotics giant Intuitive Surgical reported decelerating sales and earnings growth Thursday, leading ISRG stock to slide in after-hours trading. During the fourth quarter, Intuitive Surgical profit jumped nearly 18% to $3.48 a share. Likewise, the surgical robotics company pulled in $1.28 billion in fourth-quarter sales, growing 22% year over year to beat expectations for $1.2 billion.

  • Intel enjoys big rebound in cloud, but the future is still hazy
    Business
    MarketWatch

    Intel enjoys big rebound in cloud, but the future is still hazy

    Intel Corp. wrapped up a rocky 2019 by reporting record sales thanks to a big jump in sales of chips for data centers and cloud computing, but that rebound may just be temporary. The chip giant reported Thursday that its quarterly revenue surged past $20 billion for the first time ever at the end of 2019, fueled in part by a 19% jump in data center sales to $7.2 billion in the fourth quarter, a record performance for Intel's (INTC) second largest business. The data center arena has been feast or famine for the entire chip industry, as the sporadic ups and downs of hyperscaler companies and public cloud service providers have created doubts about where the cloud boom is headed.

  • Aurora Cannabis Could Recover in 2020 if the Stars Align
    Business
    InvestorPlace

    Aurora Cannabis Could Recover in 2020 if the Stars Align

    The Canadian cannabis sector has never marketed itself as a stable, worry-free opportunity. Once a bright spot in legal marijuana due to its massive international footprint, ACB stock plummeted in 2019 as fiscal concerns weighed more heavily than the company's potential opportunities. Since the last session of 2019, ACB stock appeared determined to kill every holding hands' patience.

  • Qorvo and Skyworks Weigh Bids for Broadcom’s RF Chip Unit
    Business
    Bloomberg

    Qorvo and Skyworks Weigh Bids for Broadcom’s RF Chip Unit

    Semiconductor makers Qorvo Inc. and Skyworks Solutions Inc. are weighing bids for Broadcom Inc.

  • FDA approves local biotech's first rare-cancer drug
    Business
    American City Business Journals

    FDA approves local biotech's first rare-cancer drug

    The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer. Tazverik is the first drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according to Epizyme.

  • Business
    Barrons.com

    10 Companies Microsoft Could Buy to Boost Its Growing Cloud Business

    It might be time for (MSFT) to go shopping. Piper Sandler analyst Brent Bracelin asserts in a research note Thursday that 2020 could be a defining year for the software giant. He argues that Microsoft (ticker: MSFT) has “a unique opportunity to further elevate its cloud leadership position through share gains and needle-moving M&A.” The company's huge run to a $1 trillion-plus valuation has been driven by the remarkable growth in its Azure cloud business, which is smaller than (AMZN)'s (AMZN) Amazon Web Services but growing faster—and Bracelin thinks the company can press its advantage with a smart deals.

  • Chipmaker Intel Smashes Fourth-Quarter Targets, Guides Higher
    Business
    Investor's Business Daily

    Chipmaker Intel Smashes Fourth-Quarter Targets, Guides Higher

    Chipmaking giant Intel late Thursday smashed Wall Street's sales and earnings targets for the fourth quarter and gave an upbeat outlook for 2020. The Intel earnings report sent INTC stock surging in extended trading. Analysts expected Intel earnings of $1.24 a share on sales of $19.2 billion, according to Zacks Investment Research.

  • A Tale of 3 Healthcare Stocks – 2 to Buy, and 1 to Sell
    Business
    TipRanks

    A Tale of 3 Healthcare Stocks – 2 to Buy, and 1 to Sell

    So when Oppenheimer announced on Wednesday that it's taken a good hard look at the healthcare industry, and come up with two stocks it's confident it can recommend buying -- and one it's pretty sure should be sold -- this is advice investors should give careful consideration. Let's find out what Oppenheimer has to say, beginning with: Regeneron is one of a strange breed in biotech -- a company that actually makes money. years in business, Tarrytown, NY-based Regeneron develops medicines to treat a wide array of illnesses, everything from age-related macular degeneration and diabetic retinopathy (Eylea) to atopic dermatitis (Dupixent) to atherosclerotic cardiovascular disease (Praluent) and l...

  • GE Stock Rebounds From Recent Slump As 'The Story Has Shifted'
    Business
    Investor's Business Daily

    GE Stock Rebounds From Recent Slump As 'The Story Has Shifted'

    General Electric is in a "budding turnaround" and should see minimal disruption from the Boeing 737 Max crisis, Morgan Stanley said. GE stock rallied back near a buy point, snapping a string of down days. Morgan Stanley analyst Joshua Pokrzywinski on Wednesday hiked his GE stock rating to overweight from equal weight and the price target to 14 from 11.

  • Business
    NerdWallet

    Who Should Consider a Roth Conversion Now?

    The new law requires most IRAs inherited by people other than spouses to be drained within 10 years, which can lead to much higher tax bills for heirs. Spouses still have the option of treating an inherited IRA as their own and taking money out over their lifetimes. At the same time, the Secure Act delayed when required minimum distributions have to begin for most retirement account owners, increasing the age for mandatory distributions from 70 1/2 to 72.